Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Further strengthens BaseLaunch's global pharma industry partnerships
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Establishing Asymchem’s first manufacturing footprint in Europe
Launch of 20 new medicines expected by 2030
Subscribe To Our Newsletter & Stay Updated
